125 related articles for article (PubMed ID: 8239537)
1. The third zinc finger of the WT1 gene is mutated in Wilms' tumour but not in a broad range of other urogenital tumours.
Quek HH; Chow VT; Tock EP
Anticancer Res; 1993; 13(5A):1575-80. PubMed ID: 8239537
[TBL] [Abstract][Full Text] [Related]
2. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor.
Barbosa AS; Hadjiathanasiou CG; Theodoridis C; Papathanasiou A; Tar A; Merksz M; Györvári B; Sultan C; Dumas R; Jaubert F; Niaudet P; Moreira-Filho CA; Cotinot C; Fellous M
Hum Mutat; 1999; 13(2):146-53. PubMed ID: 10094551
[TBL] [Abstract][Full Text] [Related]
3. Genotype/phenotype correlations in Wilms' tumor.
Huff V
Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
[TBL] [Abstract][Full Text] [Related]
4. Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour.
Grubb GR; Yun K; Reeve AE; Eccles MR
Oncogene; 1995 Apr; 10(8):1677-81. PubMed ID: 7731725
[TBL] [Abstract][Full Text] [Related]
5. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
6. Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome.
Baird PN; Groves N; Haber DA; Housman DE; Cowell JK
Oncogene; 1992 Nov; 7(11):2141-9. PubMed ID: 1331933
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of the remaining allele of the WT1 gene in a Wilms' tumour from a WAGR patient.
Brown KW; Watson JE; Poirier V; Mott MG; Berry PJ; Maitland NJ
Oncogene; 1992 Apr; 7(4):763-8. PubMed ID: 1314370
[TBL] [Abstract][Full Text] [Related]
8. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma.
Park S; Schalling M; Bernard A; Maheswaran S; Shipley GC; Roberts D; Fletcher J; Shipman R; Rheinwald J; Demetri G
Nat Genet; 1993 Aug; 4(4):415-20. PubMed ID: 8401592
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity for chromosome region 11p15 in Wilms' tumours is not related to HRAS gene transforming mutations.
Baird P; Wadey R; Cowell J
Oncogene; 1991 Jul; 6(7):1147-9. PubMed ID: 1861864
[TBL] [Abstract][Full Text] [Related]
10. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.
Little MH; Holmes G; Pell L; Caricasole A; Duarte A; Law M; Ward A; Wainwright B
Oncogene; 1996 Oct; 13(7):1461-9. PubMed ID: 8875984
[TBL] [Abstract][Full Text] [Related]
11. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours.
Dallosso AR; Hancock AL; Brown KW; Williams AC; Jackson S; Malik K
Hum Mol Genet; 2004 Feb; 13(4):405-15. PubMed ID: 14681303
[TBL] [Abstract][Full Text] [Related]
12. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour.
Pelletier J; Bruening W; Li FP; Haber DA; Glaser T; Housman DE
Nature; 1991 Oct; 353(6343):431-4. PubMed ID: 1654525
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.
Pelletier J; Bruening W; Kashtan CE; Mauer SM; Manivel JC; Striegel JE; Houghton DC; Junien C; Habib R; Fouser L
Cell; 1991 Oct; 67(2):437-47. PubMed ID: 1655284
[TBL] [Abstract][Full Text] [Related]
14. Germline intronic and exonic mutations in the Wilms' tumour gene (WT1) affecting urogenital development.
Bruening W; Bardeesy N; Silverman BL; Cohn RA; Machin GA; Aronson AJ; Housman D; Pelletier J
Nat Genet; 1992 May; 1(2):144-8. PubMed ID: 1302008
[TBL] [Abstract][Full Text] [Related]
15. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
16. A point mutation found in the WT1 gene in a sporadic Wilms' tumor without genitourinary abnormalities is identical with the most frequent point mutation in Denys-Drash syndrome.
Akasaka Y; Kikuchi H; Nagai T; Hiraoka N; Kato S; Hata J
FEBS Lett; 1993 Feb; 317(1-2):39-43. PubMed ID: 8381368
[TBL] [Abstract][Full Text] [Related]
17. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
Park S; Tomlinson G; Nisen P; Haber DA
Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
19. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
[TBL] [Abstract][Full Text] [Related]
20. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
